It occasionally happens that someone in the allopathic community tells the truth. It doesn't happen that often, so it's worth bookmarking for later reference. In the first article, a vice-president of Glaxo Smith Kline admits that the majority of people are not helped by the allopantic drugs they take
The vast majority of drugs - more than 90 per cent - only work in 30 or 50 per cent of the people," Dr Roses said. "I wouldn't say that most drugs don't work. I would say that most drugs work in 30 to 50 per cent of people. Drugs out there on the market work, but they don't work in everybody."
It seems that the problem of patient individuality bedevils the research protocol of allopathic medicine. Clinical trials do a good job of showing if a certain class of people is helped by a drug, but has no way of determining who within
the class will be helped. And the latter, of course, is what the patient consulting a doctor is most concerned with.
In the second article, a researcher explains why there's furor over swine flu
, a novel but relatively mild strain, instead of some other disease:
It's easy: They can't make money with it. With rhinoviruses, RSV and the majority of the other viruses, it's hard to make a lot of money or a career out of it. Against influenza, though, there are vaccines, and there are drugs you can sell. And that's where the big money from the pharmaceuticals industry is. It makes sure that research on influenza is published in the good journals. And that's why you have more attention being paid there, and the entire research field becomes interesting for ambitious scientists.
Much of what one gets from the mass media is either trivia, placed there for its entertainment value, or scare stories, placed by those who plan to profit from your fear.